Punit (@punitbansal14) header
Punit (@punitbansal14) profile picture

Pharmacologist | Drug Discovery | Biosimilars | Disease Management | Mountaineer & Avid Traveler (50+ countries) Tweets are for educational purpose only

Joined April 2011
Hexavalent Vaccine | Polio Outbreak | bOPV Vaccine 📸1: Gavi Board & Polio Oversight Board Recommendation bOPV + Hexavalent Combination for WHO African & Eastern Mediterranean At the request of the joint board, the partnerships are working together to improve the targeting and coverage of routine vaccines (bOPV and IPV/hexavalent) in key geographies, and implement a more systematic, comprehensive approach to integration during and outside of campaigns in select geographies of the WHO African and Eastern 📸2: Kenya Immunization Policy 2026 (bOPV + Hexavalent) Hexavalent along with 3 doses of bOPV Vaccine both are given to Infants in Kenya 📸3: Panacea Biotec EasySix (Hexavalent Vaccine) Registration and Approval in March 2025 📸4: Panacea - Expected Vaccine Orders to be executed 2026 to 2028 bOPV vaccine - Panacea bOPV Orders received (691.4 Cr) - Dec 24 to Aug 26
3
1,792
SGLT2i | Patient Share (T2DM, HF & CKD) | Dapagliflozin 📸1: Kopran EU-CEP Approval of Dapagliflozin - Nov 2026 📸2 - Kopran Commercialization of SGLT-2i – Dapagliflozin, Canagliflozin & Empagliflozin 2026 - We have developed and started successfully marketing cardiac products like Ticagrelor, Rivaroxaban and Apixaban and in the Diabetes already commercialized Dapagliflozin and are launching Empagliflozin though in the domestic markets. We await regulatory approvals in the international markets so that we can launch these products once the patent expires. 📸3: Farxiga (Dapagliflozin) Patient Share - Growth driven by new patient share in Chronic Kidney Disease (CKD) & Heart Failure (HF) 📸4: Farxiga (Dapagliflozin) Sales Growth 2014 to 2025 2014 - $208 million 2019 - $1543 million 2025 - $8492 million
7
1,658
Ibuprofen | APIs & Formulations | Long-Term Contracts IOL Chemicals - Ibuprofen, Formulation & Chemicals Business Contracts FY27 to FY28 - Additional Earnings FY27 management comments on Earnings We are very sure about that, we will be achieving it, I think we will be remaining to that level, perhaps little bit improved. But on a conservative side, we say 27 by 27, this, I think it's around mid to high teen growth numbers. FY28 management comments on Earnings with Additional revenue Generally, our pharmaceuticals investment has 1.75x to 2x top line. But again, as a disclaimer, this is a mix of so many other factors, including the geography where we are selling, the customers, the long-term arrangement and the short-term arrangement, and obviously, the market cycles as well. FY28 Growth Indicators Ibuprofen API Capacity Expansion CDMO Formulation Contract Chemical Contract Long-Term Manufacturing
1
1
1,619
Kerendia | Treatment Approach | CKD & HF 📸1: Structural and Pharmacological Properties of MRAs - Kerendia High selectivity for the MR over other steroid hormone receptors, which prevents antiandrogenic and progestational side effects 📸1: HF is a complex disease with major differences in each subtype, requiring different treatment approaches 🫀HFmrEF (LVEF 41%-49%) 🫀HFpEF (LVEF ≥50%) 📸2: Kerendia Approvals: Patient Category & Expanded Indications - Effect on Sales Growth Kerendia Sales Growth FY22 - €108 m FY23 - €270 m FY24 - €463 m FY25 - €829 m 9MFY26 - €977 m July 2021 - FDA Approves Kerendia for Treatment of Patients with CKD Associated with Type 2 Diabetes July 2025 - FDA Approves Kerendia to Treat Patients with HF with LVEF 240% Following Priority Review March 2026 - Bayer - Finerenone Phase III Non-Diabetic CKD 2025 Sept 2026 - USFDA approved Kerendia in Patients with CKD associated with Type 1 diabetes
1
1,588
Enhertu | Breast Cancer (Brain Metastasis) | Datroway 📸1: ESMO 2026 - Datroway (TNBC) & Enhertu (HER2 +ve Breast Cancer) both - Additional Efficacy in Brain Metastases Datroway could hold great promise as a treatment for TNBC brain metastases, which about a third of people with metastatic TNBC will develop Adding Enhertu bests THP for HER2-positive brain metastases Up to 50% of people with metastatic HER2-positive breast cancer develop brain metastases 📸2: Dishman - Increased Sales Force + Combination DS/DP CDMO Package Increased Sales Force: Specifically on the sales activities, we have increased our sales force. We have increased on both sites, on the Carbogen site, but also on the Dishman Carbogen site in India. DS/DP CDMO Package: Another area where we make progress is the combination drug, substance-drug product. We have started now to offer this entire package to the market, so that the customer can come in the drug substance side and take the materials through the drug product. So, he has only one supplier to deal with, which is Carbogen Amcis. Collaboration Manufacturing Unit: Collaboration with Dishman in India and Carbogen Amcis in Europe is progressing very well. We have multiple products and projects together. We have also now the first API, where we transferred from Europe, from our Carbogen Amcis site to Dishman, to be in a better position in terms of cost base, and that we can get more and more attractive prices also on the market. This project has been initiated, and I'm confident that this will be a great success also in the future.
2
2
1,602
Tulathromycin | Bovine Respiratory Disease | Partnership Model 📸1: Viyash - Tulaject (Tulathromycin) own brand and in Partnerships – Launched in US, UK, LATAM, Asia, Europe & Canada 📸2 & 3: Viyash established a partnership with Axience, France - Tulaject (Tulathromycin) Animal Health Injectable Manufacturing - Entry Barrier in Regulated Markets
9
1,927
Small Molecule ➡️ Hormone Therapy ➡️ TransCON MFG 📸1: Dishman Dedicated Facility for Hormone Based Product & Innovator Growth Dishman - We want to have like a dedicated facility for hormone-based molecule 📸2: Carbogen TransCon Multi-Year Supply Agreements with Ascendis 📸3: Yorvipath (TransCon PTH) - Sales Growth & On-going Label Expansion Trial - FY24 to Q2FY26 FY24 = €28.7 mn FY25 = €477 mn 9MFY26 = €740 mn
1
8
2,555
bOPV | Poliovirus Strains | UNICEF Agreements 📸1: Comparison of bOPV, IPV, & nOPV vaccines bOPV vs. IPV: bOPV is superior at stopping the spread of the virus in a community (intestinal immunity), whereas IPV is superior at providing individual immunity against paralysis without any risk of vaccine-derived paralysis. 📸2: Global bOPV Requirements - UNICEF estimates global annual demand to be around 1.3 billion doses - ~40 countries are self-procuring, including the Govt of India as the second largest procurer after UNICEF (Ref: UNICEF) 📸3: Panacea - Expected Vaccine Orders to be executed 2026 to 2028 bOPV vaccine - Panacea bOPV Orders received (691.4 Cr) - Dec 24 to Aug 26
4
1,591
Non-Ibuprofen | Capacity Expansion | EU Dependency 📸1: IOL Chemicals - Non-Ibuprofen Business 2018 to H1FY27 - Backward Integration Capacity Expansion & Utilization Change in Business Momentum Non-Ibuprofen Non-Ibuprofen FY18 - 5.6% Non-Ibuprofen FY21 - 18.0% Non-Ibuprofen FY24 - 34.0% Non-Ibuprofen FY26 - 37.0% 📸2: IOL Chemicals - Non-Ibuprofen Business Q4FY26 to Q2FY27 Non-Ibuprofen APIs Q4FY26 = 38% Q4 FY26 was particularly encouraging for us as the company reported its highest-ever quarterly revenue, supported by cost optimisation, improving product mix and enhanced capacity utilisation across key product lines. Non-Ibuprofen APIs Q1FY27 = 43% Non-ibu products contributed 43% of pharmaceutical revenue in Q1 FY27 compared with 36% in Q1 FY26, with revenue growing 67% year-on-year basis, and emerging as a key driver of growth in our pharma business. Non-Ibuprofen APIs Q2FY27 = 45% Our non-ibuprofen portfolio maintained its growth momentum, registering approximately 70% Y-o-Y revenue growth during Q2 and contributing 45% of pharmaceutical revenue, compared with 38% in the corresponding quarter last year. This reflects the increasing scale and contributions of our diversified API portfolio.
1
1,556
Carbapenems | Meropenems | Market Share 📸1: Kopran - Carbapenems API Sales Trend - 2021 to H1FY27 - Meropenem Domestic Share & Global Share Meropenem, in India, we are selling to every player. There is no customer concentration as far as molecules are concerned. Meropenem Global Market = $1.4 bn & Global Req. 262 MT Kopran Meropenem Global Share = 20% Emerging Market/Semi-Regulated Market Volume Growth - 20% 📸2: Kopran is a leading manufacturer of Carbapenems The launch of newer penems like Faropenem, Biapenem and Ertapenem and further pipeline products in development like Tabipenem and Imipenem gives us the entire basket of Carbapenems to make us a leading and well recognized Carbapenem manufacturer. We are the only company manufacturing Biapenem in India and have launched it in the international markets also. The complete range of penems which are the fourth-generation antibiotics reduces our risk due to price fluctuation.
1
8
1,876
India Business | Animal Health | Partnership Model 📸1: Viyash Approach to the Indian Animal Health Business 2021 – Agreement with Zoetis for the distribution of Ruminant Products 2025 – Agreement with Laxness for the distribution of Poultry Biosecurity Products 2026 - Partnership with Boehringer for the distribution of Companion Animal Products 📸2: Viyash Business Performance in India - Q1FY27 & Q2FY27 Q1FY27 - We are also seeing strong growth in domestic market as well (up 60%), and here we are looking to expand our fieldforce and product portfolio further to grow aggressively Q2FY27 - Indian formulation also witnessed strong growth across both own and distributed products. As you know, we distribute products India for BI on companion animals
17
2,113
Linker Stability➡️Datroway & Enhertu⬅️Linker Chemistry 📸1: Datroway – Mechanism Differentiation Linker and Payload Chemistry (Anti-TROP2 – (Datroway vs Others) Trodelvy's Profile: Its payload is SN-38 (the active metabolite of irinotecan). This specific payload is highly myelosuppressive. Severe drops in white blood cells (neutropenia) are very common, putting patients at risk for infections. Datroway's Profile: Its payload is DXd (a topoisomerase| inhibitor derivative). For reasons tied to its unique linker and chemical structure, Datroway is much more sparing on the bone marrow. Astrazeneca/Diachii - Higher Linker Stability "Yes, we're delighted with the Tropion-Breast02 data that was presented at ESMO. I think this does speak to the actual design of this ADC, which, similar to the Enhertu design, is based on linker stability. It is really important to have linker stability so that you're actually delivering a higher proportion of the payload to the tumor cells and less exposure in the peripheral circulation. That drives the difference in terms of the bone marrow toxicity profile that you see with Datopotamab deruxtecan compared to some other TROP2-based ADCs 📸2: Dishman - Datroway/Enhertu Commercial Order till FY28 Received Yeah, so starting with the first part, yeah, so the molecule has been performing quite well. And it has been getting more and more approvals as well. And we supply the linker as well as the payload. So yeah, I mean, we have the purchase orders in hand for the next years. And that is the reason we are quite confident about this particular project.
1
1
10
2,170
Paclitaxel | Regulatory Approvals | FDA Indications 📸1: Paclitaxel is FDA-approved for Breast Cancer, Ovarian Cancer, NSCLC & AIDS-related Kaposi Sarcoma Paclitaxel remains an important component of platinum-based chemotherapy and selected immunotherapy-containing regimens Panacea - Geographical Approach for Paclitaxel 📸2-4: Panacea Apotex Paclitaxel Profit Sharing (USA & Canada), UKMHRA Approval & Africa Panacea Apotex - Paclitaxel Profit Share Canada & USA Panacea - Paclitaxel UKMHRA Approval - March 2026 Panacea - Paclitaxel Africa Approval - Feb 2026
1
7
1,954
EU Dependency | Ibuprofen | Paracetamol | Metformin 📸1: Top APls among identified therapeutic areas have been assessed to map most relevant APIs for European Union based on foreign dependency EU Dependency (100%) – Paracetamol & Ibuprofen EU Dependency (80%) – Metformin EU Dependency (60%) - Pantoprazole 📸2: IOL Chemicals - Ibuprofen, Paracetamol & Metformin - Capacity Expansion, Capacity Utilization & Orders Q4FY26 - And we were expecting these demand of especially ibuprofen from October 2025 onwards, and that has happened. And we anticipate that this level will maintain upcoming four to six quarters. Q2FY27 - In terms of order book, you mentioned of four to six quarters. - Primarily for Ibuprofen , paracetamol and metformin
2
8
1,702
Pharma APIs | Meropenem | Q1FY27 & Q2FY27 📸1: Kopran - API Revenue Q1FY27 & Q2FY27 - Domestic Increased by 54% - Meropenem Driven - Kopran: Meropenem Sales 20% of Total Revenue - Kopran : Meropenem: in India, we are selling to every player There is no customer concentration as far as molecules are concerned 📸2: Kopran - APIs Operational Highlights Q1FY27 & Q2FY27 Total API revenue in Q1FY27 = ₹95.38 cr Total API revenue in Q2FY27 = ₹123.21 cr 📸3: Kopran – Carbapenems API Operational Highlights Q1FY27 & Q2FY27 Carbapenems (%) API revenue in Q1FY27 = ₹44.88 (47.0 % of API revenue) Carbapenems (%) API revenue in Q2FY27 = ₹82.49 cr (67.0% of API revenue)
1
14
2,097
Animal Health | Emerging Markets | Formulations 📸1: Viyash Animal Health Market & Product Expansions - Emerging Markets Brazil - Nutraceutical team with its own development in Brazil & a dedicated team in Brazil for Companion animals 📸2: Viyash Turkey, Brazil, Mexico - Business Performance Q1FY27 Emerging markets, mainly Turkey, Brazil, we have a very strong product pipeline, of course. Few launches also happened last quarter. And both countries started growing in volume. Because from last year, we are seeing the volume growth. These are the three countries, Turkey, Brazil, Mexico. So, all are doing extremely good on this business. 📸3: Viyash Turkey, Brazil, Mexico - Business Performance Q2FY27 So coming to that 39%, we are very confident actually this growth. Quarter on quarter, it can change here and there, but when there is a launch, it can offset. Last quarter, we had launch, last two quarters. But that has very stabilized now. Volume is growing. Turkey also, we are expanding, optimizing the capacity. It will grow further from next year onwards. Couple of new launches are coming. It is the both
2
21
2,537
HER2 ADC | Drug Linker Capacity | Enhertu (Bystander Effect) 📸1: Enhertu vs Kadcyla - Sales Growth 2019 to H12026 Kadcyla and Enhertu historical sales 📸2: Utilization of Trastuzumab for Daiichi Enhertu ADC - HER2 Patient Conversion (Safety & Efficacy) Example from Roche (Innovator of Herceptin & Later Kadcyla ADC) Herceptin - Trastuzumab Kadcyla - Trastuzumab Emtansine (Low DAR Ratio) Enhertu - Trastuzumab deruxtecan (High DAR Ratio) Roche came up with a companion diagnostic approach for HER2 Enhertu - More HER2 Patient Conversion for Enhertu (Safety & Efficacy) 📸3: Dishman collaboration with Japanese Innovator - ADC Drug Linker & Conjugation Capacity Expansion The current capacity we have is based on the first forecast the client came to us with, and as soon as the customer realized that he got more indications which were successfully tackled, he also came to us and asked for bigger capacities. And as we were at that time currently limited in capacity, we agreed to joint investment & now we get the second round
1
1
7
2,253
Q1FY27 | Chemical Segment (Capacity Utilization) | Q2FY27 📸1: IOL Chemicals Management Q2FY27 – Chemical Segment Q2FY27 Chemical Segment - Recorded a significant improvement, supported by healthy demand across products. The segment's EBIT contribution increased to approx 7% from 1% in the corresponding quarter last year Capacity Utilization Q2FY27 (100%) - We have used 100% of appropriate capacity for both Ethyl Acetate, Acetic Anhydride, and prices are also better in this space. So this is contributor to our chemical segment 📸2: IOL Chemicals Management Q1FY27 – Chemical Segment Q1FY27 Chemical Segment - The Chemicals business delivered 29% YoY revenue growth and 193% YoY EBIT growth, supported by improved operational efficiencies, disciplined and efficient raw-material procurement, better realisations & higher exports Capacity Utilization Q1FY27 (100%) - So we have got a better EBITDA margin in this quarter. And you see we have also increased the capacities of both Ethyl Acetate and Acetic Anhydride and we have done better in this quarter. Increased exports in Chemical segment also contributed for this
1
7
1,736
Neuromodulator | CNS Therapy | Pregabalin 📸1: Kopran Technology Transfer for new products, e.g., Lymecycline, Biapenem, Pregabalin (Enzyme route) Kopran Neuromodulator Sales Growth (2023 to 2026) FY23 – INR 1664 lakhs FY24 – INR 2208 lakhs FY25 – INR 2378 lakhs FY26 – INR 2551 lakhs 📸2: Kopran Management on Pregabalin (Exports to China) We are also in the process of tying up for exports to China for products like Pregabalin, Faropenem, Tabipenem, Macitentan, Buspirone & Edoxaban
2
7
2,014
bOPV | UNICEF Contract | Polio Outbreak 📸1: bOPV tender award from UNICEF was of $100 million distributed among 5 companies 1. Aug 2026 - $100 million 2. Dec 2025 - $144 million Panacea contribution = $35.6 million + $8.02 million = $43.8 million nearly 18% share of supplies 📸2: UNICEF Dec 2025 contract, in which there are 3 awards given for bOPV for 2026 to 2030 Serum Institute - $81 million Panacea Biotec - $36 million Beijing Institute of Biologicals - $28 million 📸3: Panacea Biotec - 2023, 2024, 2025 & 2026 bOPV Vaccine orders - 691.4 cr Dec-24 - 127 cr Apr-25 - 44 cr Oct-25 - 127.2 cr Oct-25 - 315 cr Aug-26 - 78.2
6
1,695